qbs10072s
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04430842)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Head and Neck Neoplasms · Phase 1
- Kidney Neoplasms · Phase 1
- Liver Neoplasms · Phase 1
- Lung Neoplasms · Phase 2
- Melanoma · Phase 1
- Meninges · Phase 2
- Mesothelioma · Phase 1
- Neuromuscular Diseases · Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Sarcoma · Phase 1
- Stomach Neoplasms · Phase 1
- Thymoma · Phase 1
- Tongue Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Urologic Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- L-type amino acid transporter 1INHIBITOR
SLC7A5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06810804 | Phase 2 | Feb 28, 2025 | Chinese Academy of Medical Sciences, Nantong Bencao Quadriga Medical Technology Co. Ltd. |
| NCT05305365 | Phase 2 | Aug 16, 2022 | Stanford University |
| NCT04430842 | Phase 1 | Jun 30, 2020 | Novotech, Quadriga Biosciences, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Nantong Bencao Quadriga Medical Technology Co. Ltd. | For profit | 1 | 1 | 1 | 2025 |
| Novotech | For profit | 1 | 0 | 1 | 2020 |
| Quadriga Biosciences, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2022 |
5 organizations
Page 1 / 1